Examkin

Soru

Zorluk: ZorInfectious Diseases

An internal medicine team is reviewing the culture data for a patient admitted to the hospital 4848 hours ago for septic shock secondary to a complicated urinary tract infection. The patient, who has a history of benign prostatic hyperplasia, initially presented with marked hypotension, flank pain, and a temperature of 39.4∘C39.4^\circ\text{C} (102.9∘F102.9^\circ\text{F}). He was aggressively resuscitated with intravenous crystalloids and started on broad-spectrum empiric therapy with intravenous piperacillin-tazobactam.

He is now hemodynamically stable, has been afebrile for the past 1212 hours, and his leukocytosis is resolving. He is currently unable to take medications by mouth due to severe postoperative nausea and vomiting from a recent, unrelated orthopedic procedure.

Final culture results from both blood and urine demonstrate the presence of *Escherichia coli*. The isolate's susceptibility report is as follows:

* Ampicillin: Resistant
* Trimethoprim-sulfamethoxazole: Resistant
* Ceftriaxone: Susceptible
* Cefepime: Susceptible
* Piperacillin-tazobactam: Susceptible
* Meropenem: Susceptible

Based on the principles of antimicrobial stewardship, which of the following is the most appropriate next step in pharmacotherapy?

  1. Transition to intravenous ceftriaxoneCevap
  2. B
    Maintain therapy with intravenous piperacillin-tazobactam
  3. C
    Transition to intravenous cefepime
  4. D
    Transition to intravenous meropenem
  5. E
    Add intravenous gentamicin to the current regimen

Cevap

The most appropriate step is to transition the patient to intravenous ceftriaxone.
The correct action is transitioning to intravenous ceftriaxone. A core tenet of antimicrobial stewardship is de-escalation: once a specific pathogen and its susceptibility profile are identified, empiric broad-spectrum antimicrobial therapy should be narrowed to the most targeted agent available. This patient has Escherichia coli bacteremia and pyelonephritis that is highly susceptible to ceftriaxone. Ceftriaxone effectively treats the infection while sparing broader spectrum agents like piperacillin-tazobactam, cefepime, and meropenem, all of which possess unnecessary anti-pseudomonal and/or broader anaerobic activity that the patient does not need. Because the patient cannot take oral medications due to severe nausea, a step-down to an oral agent (which would otherwise be preferred) is contraindicated, making intravenous ceftriaxone the ideal definitive choice.

Adım Adım Çözüm

1
Interpret the clinical status and definitive culture results.
The patient is clinically stable, and cultures have identified Escherichia coli that is susceptible to multiple beta-lactam antibiotics.
Evaluating clinical trajectory alongside definitive microbiologic data is required before modifying an empiric antimicrobial regimen.
2
Apply the principles of antimicrobial stewardship.
De-escalation from empiric broad-spectrum therapy (piperacillin-tazobactam) to the most targeted, narrow-spectrum effective agent is indicated.
De-escalation minimizes the risk of antimicrobial resistance, collateral damage to the microbiome, and adverse drug effects.
3
Select the optimal targeted therapeutic agent based on the antibiogram.
Intravenous ceftriaxone is selected as the definitive therapy.
Ceftriaxone effectively targets the susceptible isolate without providing unnecessary anti-pseudomonal or broad anaerobic coverage. An intravenous route is necessary due to the patient's inability to tolerate oral intake.

Anahtar Kavram

Antimicrobial Stewardship and De-escalation
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru